These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 38614299

  • 1. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T, Saigusa D, Kato K, Fukuuchi T, Koshiba S, Yamamoto M, Suzuki N.
    Life Sci; 2024 Jun 01; 346():122641. PubMed ID: 38614299
    [Abstract] [Full Text] [Related]

  • 2. Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice.
    Nakai T, Iwamura Y, Kato K, Hirano I, Matsumoto Y, Tomioka Y, Yamamoto M, Suzuki N.
    Blood Adv; 2023 Aug 08; 7(15):3793-3805. PubMed ID: 37146271
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M.
    Eur J Pharmacol; 2019 Sep 15; 859():172532. PubMed ID: 31301309
    [Abstract] [Full Text] [Related]

  • 7. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N, Wish JB.
    Am J Kidney Dis; 2017 Jun 15; 69(6):815-826. PubMed ID: 28242135
    [Abstract] [Full Text] [Related]

  • 8. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
    Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U.
    PLoS One; 2014 Jun 15; 9(11):e111838. PubMed ID: 25392999
    [Abstract] [Full Text] [Related]

  • 9. Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
    Beck H, Jeske M, Thede K, Stoll F, Flamme I, Akbaba M, Ergüden JK, Karig G, Keldenich J, Oehme F, Militzer HC, Hartung IV, Thuss U.
    ChemMedChem; 2018 May 23; 13(10):988-1003. PubMed ID: 29485740
    [Abstract] [Full Text] [Related]

  • 10. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E, Cho KH, Harris ST, Flindt NR, Watt RK, Pai AB.
    Expert Opin Investig Drugs; 2020 Aug 23; 29(8):831-844. PubMed ID: 32476498
    [Abstract] [Full Text] [Related]

  • 11. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
    Noonan ML, Clinkenbeard EL, Ni P, Swallow EA, Tippen SP, Agoro R, Allen MR, White KE.
    Physiol Rep; 2020 Jun 23; 8(11):e14434. PubMed ID: 32476270
    [Abstract] [Full Text] [Related]

  • 12. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Curr Opin Nephrol Hypertens; 2020 Jul 23; 29(4):414-422. PubMed ID: 32452915
    [Abstract] [Full Text] [Related]

  • 13. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
    Li L, Nakano D, Zhang A, Kittikulsuth W, Morisawa N, Ohsaki H, Suzuki N, Yamamoto M, Nishiyama A.
    J Pharmacol Sci; 2020 Dec 23; 144(4):229-236. PubMed ID: 33070842
    [Abstract] [Full Text] [Related]

  • 14. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
    Kato S, Ochiai N, Takano H, Io F, Takayama N, Koretsune H, Kunioka EI, Uchida S, Yamamoto K.
    J Pharmacol Exp Ther; 2019 Dec 23; 371(3):675-683. PubMed ID: 31585986
    [Abstract] [Full Text] [Related]

  • 15. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
    Ogawa C, Tsuchiya K, Maeda K.
    Int J Mol Sci; 2023 Feb 03; 24(3):. PubMed ID: 36769359
    [Abstract] [Full Text] [Related]

  • 16. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S, PHI112844 Investigators.
    Am J Kidney Dis; 2016 Jun 03; 67(6):861-71. PubMed ID: 26827289
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
    Fukuda T, Kuribayashi T, Takano R, Sasaki K, Tsuji T, Niitsu Y, Ishii K, Hashimoto M, Baba D, Ito S, Tanaka N.
    Bioorg Med Chem Lett; 2024 Aug 01; 108():129799. PubMed ID: 38754564
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
    Katagiri N, Hitomi H, Mae SI, Kotaka M, Lei L, Yamamoto T, Nishiyama A, Osafune K.
    Sci Rep; 2021 Feb 16; 11(1):3936. PubMed ID: 33594180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.